NeOnc Technologies — Third Quarter 2026 Earnings Summary

NeOnc Technologies Holdings, Inc. reported a net loss of $4.4 million for the third quarter of 2026, a decrease from $8.6 million in the same period the previous year. The company raised $15 million through a registered direct offering and used part of the proceeds to redeem its Series A Convertible Preferred Stock, eliminating potential shareholder dilution. Clinically, the Phase 2a study for intranasal NEO100 met its primary endpoint in patients with recurrent IDH1-mutant high-grade glioma, showing a six-month progression-free survival of 48.9%. Additionally, NeOnc entered a memorandum of understanding with the Department of Health in Abu Dhabi to advance CNS oncology research and clinical development.